Wednesday, July 8, 2026

Drug profile · INN

almotriptan malate

almotriptan malate (ALMOTRIPTAN MALATE) is a serotonin 1f (5-ht1f) receptor agonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — almotriptan malate
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.89

Quick answer

almotriptan malate (ALMOTRIPTAN MALATE) is a serotonin 1f (5-ht1f) receptor agonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN almotriptan malate
Brand ALMOTRIPTAN MALATE
Mechanism Serotonin 1f (5-HT1f) receptor agonist
Target 5-hydroxytryptamine receptor 1B
Route ORAL
Formulation TABLET

Mechanism of action

Serotonin 1f (5-HT1f) receptor agonist

Primary target: 5-hydroxytryptamine receptor 1B

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. eletriptan hydrobromide Serotonin 1b (5-HT1b) receptor agonist
  2. frovatriptan succinate Serotonin 1b (5-HT1b) receptor agonist
  3. rizatriptan benzoate Serotonin 1d (5-HT1d) receptor agonist
  4. sumatriptan Serotonin 1b (5-HT1b) receptor agonist
  5. sumatriptan succinate Serotonin 1d (5-HT1d) receptor agonist
  6. zolmitriptan Serotonin 1d (5-HT1d) receptor agonist

Frequently asked questions

What is almotriptan malate?

almotriptan malate (ALMOTRIPTAN MALATE) is a serotonin 1f (5-ht1f) receptor agonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for almotriptan malate?

ALMOTRIPTAN MALATE is a marketed brand name for almotriptan malate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of almotriptan malate?

almotriptan malate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.